Our response to COVID-19

Anette Vibeke Petersen is operator at Novo Nordisk in Denmark

With the COVID-19 pandemic escalating, President and chief executive officer of Novo Nordisk, Lars Fruergaard Jørgensen makes the case for resilience, collective action and learning from past experience in the face of an unprecedented challenge.

Our response to COVID-19

Our updates during the COVID-19 pandemic

We offer 0 job opportunities

Turning scientific ideas into medicines

From formulating protein molecules in a tablet to stem cell research, our scientists are always striving for the next breakthrough.

Read more about our work in the lab


Making our medicines accessible and affordable

For many people with diabetes, insulin is an essential, life-saving medicine. It’s our ambition that everyone who needs insulin has access to it.

Read more about our and affordability programmes


Are you looking for information on our US Affordability programs?

Please visit NovoCare

Preventing the rise of type 2 diabetes

The huge rise in type 2 diabetes around the world is catastrophic. Uncontrolled, this rise is not sustainable for anyone – people, health systems, businesses or economies. Bending the curve on diabetes is therefore crucial to all of us. 

Read about our efforts to prevent type 2 diabetes